




# Burkina Faso



African Region

## I. Epidemiological profile


Population (UN)	2015	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	18,100,000	100	Plasmodium species: <i>P. falciparum</i> (100%)0%
Low transmission (0-1 cases per 1000 population)	0	-	Major anopheles species: <i>An. gambiae</i> , <i>An. funestus</i> , <i>An. arabiensis</i>
Malaria-free (0 cases)	0	-	Reported confirmed cases (health facility): 7,015,446 Estimated cases: 7,000,000 [4,500,000 ; 10,000,000]
Total	18,110,000	-	Confirmed cases at community level: - Reported deaths: 5,379 Estimated deaths: 15,000 [10,000 ; 29,000]

## II. Intervention policies and strategies


Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2007	First-line treatment of unconfirmed malaria	AL; AS+AQ	2005					
	ITNs/ LLINs distributed to all age groups	Yes	1998	First-line treatment of <i>P. falciparum</i>	AL; AS+AQ	2005					
IRS	IRS is recommended	Yes	2006	Treatment failure of <i>P. falciparum</i>	QN	-					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS; QN	-					
Larval control	Use of larval control recommended	Yes	2012	Treatment of <i>P. vivax</i>	-	-					
IPT	IPT used to prevent malaria during pregnancy	Yes	2005	Dosage of Primaquine for radical treatment of <i>P. vivax</i>	-	-					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2009	Type pf RDT used	-	P.f only					
	Malaria diagnosis is free of charge in the public sector	Yes	2009								
Treatment	ACT is free of charge for all ages in public sector	No	-	<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-	AL	2005-2013	0	5.4	12.5	28 days	10	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	No	-	AS+AQ	2006-2012	0	4.5	21.5	28 days	8	<i>P. falciparum</i>
	G6PD test is a requirement before treatment with primaquine	No	-								
	Directly observed treatment with primaquine is undertaken	No	-								
	System for monitoring adverse reactions to antimalarials exists	Yes	1998								
Surveillance	ACD for case investigation (reactive)	No	-	<b>Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)</b>							
	ACD of febrile cases at community level (pro-active)	No	-	Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested		
	Mass screening is undertaken	No	-	2010-2014	Yes	Yes	Yes	Yes	<i>An. arabiensis</i> , <i>An. coluzzii</i> , <i>An. gambiae</i> s.l.		
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	Yes	-									

## III. Financing

### Sources of financing




### Government expenditure by intervention in 2015




## IV. Coverage

### Coverage of ITN and IRS




### Cases tested and treated in public sector




## V. Impact


### Cases treated



### Test positivity



### Confirmed malaria cases per 1000 and ABER



### Malaria admissions and deaths (per 100 000)

